Coridon HSV-2 vaccine shows 100% efficacy

Brisbane, Australia-based biotech Coridon has developed a DNA vaccine for herpes simplex virus 2 that showed 100% efficacy in a preclinical trial. Thanks to financial backing from Allied Healthcare Group, Coridon hopes to push the vaccine into human trials in the next year. As a DNA vaccine, the HSV-2 vax can be used both for preventative and curative measures. Article

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.